Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia

Biochemical Pharmacology

Volumn 60, Issue 5, 2000, Pages 625-634

  Melo, Tricia ^a   Ballinger, James R ^a   Rauth, A Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

2 Nitroimidazole; BRU59 21; Enzyme; Hypoxia; P450 reductase

Indexed keywords

BRU 59 21; NITROIMIDAZOLE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TECHNETIUM 99M; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DRUG ACCUMULATION; ENZYME ACTIVITY; HYPOXIA; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; TUMOR CELL;

ANIMALS; CELL HYPOXIA; CHO CELLS; CRICETINAE; HUMANS; IMIDAZOLES; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TRANSFECTION;

EID: 0034284649     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00373-7     Document Type: Article

References (39)

1. Höckel M., Schlenger K., Mitze M., Schaffer U., Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 6:1996;3-9.
2. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
3. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91.
4. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56:1996;5754-5757.
5. Chapman J.D., Engelhardt E.L., Stobbe C.C., Schneider R.F., Hanks G.E. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 46:1998;229-237.
6. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280.
7. Wedeking P., Yost F., Wen M., Patel B., Eaton S., Romero V., Linder K.E. Comparison of the biologic activity of the isomers of the Tc-99m-nitroimidazole complex BMS-194796. J Nucl Med. 36:1995;17P.
8. Melo T., Duncan J., Ballinger J.R., Rauth A.M. BRU59-21, a second-generation technetium-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med. 41:2000;169-176.
9. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., Lewis A.D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel Correlation with sensitivity to mitomycin C and EO9 . J Natl Cancer Inst. 88:1996;259-269.
10. Koch C.J., Giandomenico A.R., Iyengar C.W.L. Bioreductive metabolism of AF-2 [2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles Implications for use as hypoxic cell markers . Biochem Pharmacol. 46:1993;1029-1036.
11. Workman P. Bioreductive mechanisms. Int J Radiat Oncol Biol Phys. 22:1992;631-637.
12. Cobb L.M., Nolan J., Hackler T. Retention of misonidazole in normal and malignant tissues Interplay of hypoxia and reductases . Int J Radiat Oncol Biol Phys. 22:1992;655-659.
13. Joseph P., Jaiswal A.K., Stobbe C.C., Chapman J.D. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys. 29:1994;351-355.
14. Prekeges J.L., Rasey J.S., Grunbaum Z., Krohn K.H. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol. 42:1991;2387-2395.
15. Aboagye E.O., Lewis A.D., Tracy M., Workman P. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4544). Biochem Pharmacol. 54:1997;1217-1224.
16. Melo T., Hua H.A., Ballinger J.R., Rauth A.M. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol. 54:1997;685-693.
17. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci USA. 93:1996;456-460.
18. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., Stratford I.J. Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug tirapazamine (SR4233). Br J Cancer. 72:1995;1144-1150.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
20. 5 reductase in human tumour cells. Br J Cancer. 74:1996;1188-1193.
21. Misra V., Klamut H.J., Rauth A.M. Transfection of COS-1 cells with DT-diaphorase cDNA Role of a base change at position 609 . Br J Cancer. 77:1998;1236-1240.
22. Thorell B. Flow-cytometric analysis of cellular endogenous fluorescence simultaneously with emission from exogenous fluorochromes, light scatter and absorption. Cytometry. 2:1981;39-43.
23. Whillans D.W., Rauth A.M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res. 84:1980;97-114.
24. Taylor Y.C., Rauth A.M. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 38:1978;2745-2752.
25. Segura-Aguilar J., Cortes-Vizcaino V., Llombart-Bosch A., Ernster L., Monsalve E., Romero F.J. The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in diethylstilbestrol-induced carcinogenesis in the kidney of male Syrian golden hamsters. Carcinogenesis. 11:1990;1727-1732.
26. Tew D.G. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry. 32:1993;10209-10215.
27. O'Donnell V.B., Smith G.C., Jones O.T. Involvement of phenyl radicals in iodonium inhibition of flavoenzymes. Mol Pharmacol. 46:1994;778-785.
28. McGuire J.J., Anderson D.J., McDonald B.J., Narayanasami R., Bennett B.M. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem Pharmacol. 56:1998;881-893.
29. 5 reductase from rabbit liver cytosol Partial purification and characterization . Biochim Biophys Acta. 526:1978;42-51.
30. 5 reductase. FEBS Lett. 209:1986;49-51.
31. 5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem. 273:1998;8875-8881.
32. Chapman J.D. Hypoxic sensitizers - implications for radiation therapy. N Engl J Med. 301:1979;1429-1432.
33. Ballinger J.R., Wan Min Kee J., Rauth A.M. In vitro and in vivo evaluation of technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 37:1996;1023-1031.
34. Yasukochi Y., Masters B.S.S. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem. 251:1976;5337-5344.
35. 5 reductase . Biochem Pharmacol. 51:1996;829-837.
36. Brauers G., Archer C.M., Burke J.F. The chemical characterization of the tumour imaging agent 99mTc-HL91. Eur J Nucl Med. 24:1997;943.
37. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem Pharmacol. 51:1996;1669-1678.
38. Cowan DSM, Melo T, Park L, Ballinger JR and Rauth AM, BMS181321 accumulation in human and rodent cells: The role of P-glycoprotein. Br J Cancer 74 (Suppl 27): S264-S266, 1996.
39. Ling L., Sutherland R.M. Modulation of the hypoxic toxicity and binding of misonidazole by glucose. Br J Cancer. 54:1986;911-917.